C-AHHAumbilical cord blood-derived MSCs, regenerative medicine, stem cell therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
MEDIPOST presents itself as a global leader in stem cell therapeutics and a biotechnology company advancing life-changing innovation through cord blood-derived cell therapies and GMP-compliant CDMO services. The company states that rigorous quality systems, accumulated research and production experience, and clinical development of allogeneic umbilical cord blood-derived mesenchymal stem cell products are central to its approach.
SourceMEDIPOST presents itself as a stem cell and regenerative medicine company that believes innovative stem cell technology can expand the treatment of incurable diseases and unmet medical needs. It frames commercialization of allogeneic umbilical cord blood-derived stem cell therapies as a practical path to improve patients’ quality of life, while emphasizing rigorous research, global biotechnology leadership, and strong corporate ethics and values.
SourceMEDIPOST presents itself as a global leader in biotechnology focused on stem cell therapeutics, stating that it will continue to innovate and take on unmet medical needs through life-changing biotechnology. Its stated belief is that advanced stem cell-based products and ongoing R&D can address major conditions such as knee cartilage defects, osteoarthritis, bronchopulmonary dysplasia, and diabetic nephropathy.
Source